Enhanced eIF5A2 expression correlates with poor prognosis and poor response for chemotherapeutic drugs in patients with cancers [15], suggesting that eIF5A is a useful biomarker in the prediction of cancer prognosis and drug response. The gene discussed is EIF5A; the disease is cancer.